Johnson & Johnson and Pfizer both pruned their holdings in Aquinox Pharmaceuticals following the recent run-up in its shares.
Aquinox Pharmaceuticals (AQXP) soared recently after the company announced positive results from secondary endpoints from its Phase 2 LEADERSHIP trial with AQX-1125 in patients with bladder pain syndrome/interstitial cystitis (BPS/IC).
Aquinox’s improved quarterly earnings
As outlined by ValueWalk, Aquinox Pharmaceuticals unveiled its second quarter results wherein the clinical stage pharmaceutical company reported that its net loss declined to $4.8 million from $5.4 million in the same period a year ago. The firm ended the quarter with $29 million in cash, cash equivalents and investments.
Aquinox Pharmaceuticals reported top-line results from its LEADERSHIP Phase 2...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full Article
